Pathogenesis of nontuberculous mycobacteria infections

Clinics in Chest Medicine

Volumn 23, Issue 3, 2002, Pages 569-583

  McGarvey, Jeffery ^a   Bermudez, Luiz E ^a  

^a Kuzell Institute for Arthritis and Infectious Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ATYPICAL MYCOBACTERIUM; BACTERIAL VIRULENCE; CELL INVASION; FATALITY; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM CHELONEI; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM INTRACELLULARE; MYCOBACTERIUM KANSASII; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYNDROME DELINEATION;

HUMANS; MUCOUS MEMBRANE; MYCOBACTERIA, ATYPICAL; MYCOBACTERIUM INFECTIONS, ATYPICAL; RESPIRATORY MUCOSA; TUBERCULOSIS, PULMONARY;

EID: 0036737906     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-5231(02)00012-6     Document Type: Review

References (143)

1. Falkinham III JO. Epidemiology of infection by nontuberculous mycobacteria. Clin Microbiol Rev 1996; 9:177-215.
2. Haas CN, Meyer MA, Paller MS. The ecology of the acid-fast organisms in water supply, treatment and distribution system. J Am Water Work Assoc 1983; 75:139-44.
3. Contreras MA, Cheung OT, Sanders DE, Goldstein RS. Pulmonary infection with nontuberculous mycobacteria. Am Rev Respir Dis 1988;137:149-52.
4. Jacobson MA, Hopewell PC, Yajko DM, Hadley WK, Lazarus E, Mohanty PK, et al. Natural history of disseminated Mycobacterium avium complex infection in AIDS. J Infect Dis 1991;164:994-8.
5. Gray JR, Rabeneck L. Atypical mycobacterial infection of the gastrointestinal tract in AIDS patients. Am J Gastroenterol 1989;84:1521-4.
6. Damsker B, Bottone EJ. Mycobacterium avium-Mycobacterium intracellulare from the intestinal tracts of patients with the acquired immunodeficiency syndrome: concepts regarding acquisition and pathogenesis. J Infect Dis 1985;151:179-81.
7. Bodmer T, Miltner E, Bermudez LE. Mycobacterium avium resists exposure to the acidic conditions of the stomach. FEMS Microbiol Lett 2000;182:45-9.
8. Bermudez LE, Petrofsky M, Kolonoski P, Young LS. An animal model of Mycobacterium avium complex disseminated infection after colonization of the intestinal tract. J Infect Dis 1992;165:75-9.
9. Sangari FJ, Goodman J, Petrofsky M, Kolonoski P, Bermudez LE. Mycobacterium avium invades the intestinal mucosa primarily by interacting with enterocytes. Infect Immun 2001;69:1515-20.
10. Rosenzweig DY. Pulmonary mycobacterial infections due to Mycobacterium intracellular-avium complex. Clinical features and course in 100 consecutive cases. Chest 1979;75:115-9.
11. McGarvey J, Bermudez LE. Phenotypic and genomic analysis of the Mycobacterium avium complex reveals differences in gastrointestinal invasion and genomic composition. Infect Immun 2001;69: 7242-9.
12. Schorey JS, Holsti MA, Ratliff TL, Allen PM, Brown EJ. Characterization of the fibronectin-attachment protein of Mycobacterium avium reveals a fibronectin-binding motif conserved among mycobacteria. Mol Microbiol 1996;21:321-9.
13. Schorey JS, Li Q, McCourt DW, Bong-Mastek M, Clark-Curtiss JE, Ratliff TL, et al. A Mycobacterium leprae gene encoding a fibronectin binding protein is used for efficient invasion of epithelial cells and Schwann cells. Infect Immun 1995;63:2652-7.
14. Middleton AM, Chadwick MV, Nicholson AG, Dewar A, Groger RK, Brown EJ, et al. The role of Mycobacterium avium complex fibronectin attachment protein in adherence to the human respiratory mucosa. Mol Microbiol 2000;38:381-91.
15. Menozzi FD, Bischoff R, Fort E, Brennan MJ, Locht C. Molecular characterization of the mycobacterial heparin-binding hemagglutinin, a mycobacterial adhesin. Proc Natl Acad Sci USA 1998;95:12625-30.
16. Bermudez LE, Shelton K, Young LS. Comparison of the ability of Mycobacterium avium, M. smegmatis and M. tuberculosis to invade and replicate within HEp-2 epithelial cells. Tuber Lung Dis 1995;76:240-7.
17. Miltner E, Cirillo J, Bermudez LE. Identification of Mycobacterium avium genes associated with the ability to invade epithelial cells. Presented at the ASM General Meeting. Orlando, FL., 2001
18. Rao SP, Gehlsen KR, Catanzaro A. Identification of a beta 1 integrin on Mycobacterium avium-Mycobacterium intracellulare. Infect Immun 1992;60:3652-7.
19. Bermudez LE, Petrofsky M, Goodman J. Exposure to low oxygen tension and increased osmolarity enhance the ability of Mycobacterium avium to enter intestinal epithelial (HT-29) cells. Infect Immun 1997;65: 3768-73.
20. Bermudez LE, Young LS. Factors affecting invasion of HT-29 and HEp-2 epithelial cells by organisms of the Mycobacterium avium complex. Infect Immun 1994;62:2021-6.
21. Sangari F, Goodman J, Bermudez LW. Ultrastructural study of Mycobacterium avium infection of HT-29 human intestinal epithelial cells. J Med Microbiol 2000;49:139-42.
22. Bermudez LE, Sangari FJ. Cellular and molecular mechanisms of internalization of mycobacteria by host cells. Microbes Infect 2001;3:37-42.
23. Kim SY, Goodman JR, Petrofsky M, Bermudez LE. Mycobacterium avium infection of gut mucosa in mice associated with late inflammatory response and intestinal cell necrosis. J Med Microbiol 1998; 47:725-31.
24. Sangari FJ, Petrofsky M, Bermudez LE. Mycobacterium avium infection of epithelial cells results in inhibition or delay in the release of interleukin-8 and RANTES. Infect Immun 1999;67:5069-75.
25. Sangari FJ, Goodman J, Bermudez LE. Mycobacterium avium enters intestinal epithelial cells through the apical membrane, but not by the basolateral surface, activates small GTPase Rho and, once within epithelial cells, expresses an invasive phenotype. Cell Microbiol 2000;2:561-8.
26. Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis 1979;119: 107-59.
27. Falkinham III JO, Norton CD, LeChevallier MW. Factors influencing numbers of Mycobacterium avium, Mycobacterium intracellulare, and other mycobacteria in drinking water distribution systems. Appl Environ Microbiol 2001;67:1225-31.
28. Martinez A, Torello S, Kolter R. Sliding motility in mycobacteria. J Bacteriol 1999;181:7331-8.
29. Carter G, Drummond DC, Young LS, Bermudez LE. Characterization of Mycobacterium avium biofilm. Presented at the ICAAC Meeting. Chicago, 2001.
30. Bermudez LE, Goodman J. Mycobacterium tuberculosis invades and replicates within type II alveolar cells. Infect Immun 1996;64:1400-6.
31. Lin Y, Zhang M, Barnes PF. Chemokine production by a human alveolar epithelial cell line in response to Mycobacterium tuberculosis. Infect Immun 1998;66: 1121-6.
32. Rao SP, Hayashi T, Catanzaro A. Release of monocyte chemoattractant proteins (MCP-1) by a uman alveolar epithelial cell line in response to Mycobacterium avium. FEMS Immunol Med Microbiol 2000; 29:1-7.
33. Florido M, Appelberg R, Orme IM, Cooper AM. Evidence for a reduced chemokine response in the lungs of beige mice infected withs Mycobacterium avium. Immunology 1997;90:600-6.
34. Bermudez LE, Young LS, Enkel H. Interaction of Mycobacterium avium complex with human macrophages: roles of membrane receptors and serum proteins. Infect Immun 1991;59:1697-702.
35. Wright SD, Silverstein SC. Receptors for C3b and C3bi promote phagocytosis but not the release of toxic oxygen from human phagocytes. J Exp Med 1983;158:2016-23.
36. Bermudez LE, Young LS. Oxidative and non-oxidative intracellular killing of Mycobacterium avium complex. Microb Pathog 1989;7:289-98.
37. Segal BH, Doherty TM, Wynn TA, Cheever AW, Sher A, Holland SM. The p47(phox-/-) mouse model of chronic granulomatous disease has normal granuloma formation and cytokine responses to Mycobacterium avium and Schistosoma mansoni eggs. Infect lmmun 1999;67:1659-65.
38. Rao SP, Ogata K, Catanzaro A. Mycobacterium avium-M. intracellulare binds to the integrin receptor alpha v beta 3 on human monocytes and monocyte-derived macrophages. Infect lmmun 1993;61: 663-70.
39. Hayashi T, Rao SP, Catanzaro A. Binding of the 68-kilodalton protein of Mycobacterium avium to alpha(v)beta3 on human monocyte-derived macrophages enhances complement receptor type 3 expression. Infect Immun 1997;65:1211-6.
40. Schorey JS, Carroll MC, Brown EJ. A macrophage invasion mechanism of pathogenic mycobacteria. Science 1997;277:1091-3.
41. Bermudez LE, Parker A, Goodman JR. Growth within macrophages increases the efficiency of Mycobacterium avium in invading other macrophages by a complement receptor-independent pathway. Infect Immun 1997;65:1916-25.
42. Bermudez LE, Petrofsky M, Sangari FJ. Intracellular phenotype of Mycobacterium avium is taken into macrophages by macropinocytosis and lives within an environment that differs from the one of extracellular phenotype. Infect Immun 2001; in press.
43. Bermudez LE, Goodman J, Petrofsky M. Role of complement receptors in uptake of Mycobacterium avium by macrophages in vivo: evidence from studies using CD18-deficient mice. Infect Immun 1999; 67:4912-6.
44. Appelberg R, Pedrosa JM, Silva MT. Host and bacterial factors control the Mycobacterium avium-induced chronic peritoneal granulocytosis in mice. Clin Exp Immunol 1991;83:231-6.
45. Appelberg R, Castro AG, Gomes S, Pedrosa J, Silva MT. Susceptibility of beige mice to Mycobacterium avium: role of neutrophils. Infect Immun 1995;63: 3381-7.
46. Petrofsky M, Bermudez LE. Neutrophils from Mycobacterium avium-infected mice produce TNF-alpha, IL-12, and IL-1 beta and have a putative role in early host response. Clin Immunol 1999;91:354-8.
47. Bermudez LE, Petrofsky M, Stevens P. Treatment with recombinant granulocyte colony-stimulating factor (Filgrastin) stimulates neutrophils and tissue macrophages and induces an effective non-specific response against Mycobacterium avium in mice. Immunology 1998;94:297-303.
48. Newman GW, Guarnaccia JR, Remold HG, Kazanjian Jr. PH. Cytokines enhance neutrophils from human immunodeficiency virus-negative donors and AIDS patients to inhibit the growth of Mycobacterium avium in vitro. J Infect Dis 1997;175:891-900.
49. Ogata K, Linzer BA, Zuberi RI, Ganz T, Lehrer RI, Catanzaro A. Activity of defensins from human neutrophilic granulocytes against Mycobacterium avium-Mycobacterium intracellulare. Infect Immun 1992; 60:4720-5.
50. Sturgill-Koszycki S, Schlesinger PH, Chakraborty P, Haddix PL, Collins HL, Fok AK, et al. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science 1994;263:678-81.
51. Crowle AJ, Dahl R, Ross E, May MH. Evidence that vesicles containing living, virulent Mycobacterium tuberculosis or Mycobacterium avium in cultured human macrophages are not acidic. Infect Immun 1991;59:1823-31.
52. de Chastellier C, Lang T, Thilo L. Phagocytic processing of the macrophage endoparasite, Mycobacterium avium, in comparison to phagosomes which contain Bacillus subtilis or latex beads. Eur J Cell Biol 1995;68:167-82.
53. Zu H, Bentrup K, Miczak A, Swenson DL, Russell DG. Characterization of activity and expression of isocitrate lyase in Mycobacterium avium and Mycobacterium tuberculosis. J Bacteriol 1999;181: 7161-7.
54. Wagner D, Maser J, Lai B, Cai Z, Bermudez LE. Quantification of trace elements in the mycobacterial phagosome using a novel hard x-ray microprobe. Presented at the ASM General Meeting, Orlando, FL, 2000.
55. Barrow WW, de Sousa JP, Davis TL, Wright EL, Bachelet M, Rastogi N. Immunomodulation of human peripheral blood mononuclear cell functions by defined lipid fractions of Mycobacterium avium. Infect Immun 1993;61:5286-93.
56. Beatty WL, Rhoades ER, Ullrich HJ, Chatterjee D, Heuser JE, Russell DG. Trafficking and release of mycobacterial lipids from infected macrophages. Traffic 2000;1:235-47.
57. Sangari FJ, Carter G, Bermudez LE. Analysis of the Mycobacterium avium osmoregulated Kdp operon and trgRS, a two component regulatory system diffentially expressed in macrophages. Presented at the ASM General Meeting. Orlando, FL, 2000.
58. Berthet FX, Lagranderie M, Gounon P, Laurent-Winter C, Ensergueix D, Chavarot P, et al. Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene. Science 1998;282:759-62.
59. McKinney JD, Zu H, Bentrup K, Munoz-Elias EJ, Miczak A, Chen B, et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 2000;406:735-8.
60. Armitige LY, Jagannath C, Wanger AR, Norris SJ. Disruption of the genes encoding antigen 85A and antigen 85B of Mycobacterium tuberculosis H37Rv: effect on growth in culture and in macrophages. Infect Immun 2000;68:767-78.
61. Fratazzi C, Arbeit RD, Carini C, Remold HG. Programmed cell death of Mycobacterium avium serovar 4-infected human macrophages prevents the mycobacteria from spreading and induces mycobacterial growth inhibition by freshly added, uninfected macrophages. J Immunol 1997;158:4320-7.
62. Bermudez LE, Parker A, Petrofsky M. Apoptosis of Mycobacterium avium-infected macrophages is mediated by both tumour necrosis factor (TNF) and Fas, and involves the activation of caspases. Clin Exp Immunol 1999;116:94-9.
63. Fratazzi C, Arbeit RD, Carini C, Balcewicz-Sablinska MK, Keane J, Komfeld H, et al. Macrophage apoptosis in mycobacterial infections. J Leukoc Biol 1999; 66:763-4.
64. Balcewicz-Sablinska MK, Gan H, Remold HG. Interleukin 10 produced by macrophages inoculated with Mycobacterium avium attenuates mycobacteria-induced apoptosis by reduction of TNF-alpha activity. J Infect Dis 1999;180:1230-7.
65. Hayashi T, Catanzaro A, Rao SP. Apoptosis of human monocytes and macrophages by Mycobacterium avium sonicate. Infect Immun 1997;65:5262-71.
66. Goletti D, Weissman D, Jackson RW, Graham NM, Vlahov D, Klein RS, et al. Effect of Mycobacterium tuberculosis on H1V replication. Role of immune activation. J Immunol 1996;157:1271-8.
67. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995;151:129-35.
68. Doherty TM, Chougnet C, Schito M, Patterson BK, Fox C, Shearer GM, et al. Infection of HIV-1 transgenic mice with Mycobacterium avium induces the expression of infectious virus selectively from a Mac-1-positive host cell population. J Immunol 1999; 163:1506-15.
69. Wahl SM, Greenwell-Wild T, Peng G, Hale-Donze H, Doherty TM, Mizel D, et al. Mycobacterium avium complex augments macrophage HIV-1 production and increases CCR5 expression. Proc Natl Acad Sci USA 1998;95:12574-9.
70. Kallenius G, Koivula T, Rydgard KJ, Hoffner SE, Valentin A, Asjo B, et al. Human immunodeficiency virus type 1 enhances intracellular growth of Mycobacterium avium in human macrophages. Infect Immun 1992;60:2453-8.
71. Schnittman SM, Psallidopoulos MC, Lane HC, Thompson L, Baseler M, Massari F, et al. The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science 1989;245: 305-8.
72. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-300.
73. Newman GW, Kelley TG, Gan H, Kandil O, Newman MJ, Pinkston P, et al. Concurrent infection of human macrophages with HIV-1 and Mycobacterium avium results in decreased cell viability, increased M. avium multiplication and altered cytokine production. J Immunol 1993;151:2261-72.
74. Shiratsuchi H, Johnson JL, Toossi Z, Ellner JJ. Modulation of the effector function of human monocytes for Mycobacterium avium by human immunodeficiency virus-1 envelope glycoprotein gp120. J Clin Invest 1994;93:885-91.
75. Altare F, Durandy A, Lammas D, Emile JF, Lamhamedi S, Le Deist F, et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 1998;280:1432-5.
76. Dorman SE, Holland SM. Mutation in the signal-transducing chain of the interferon-gamma receptor and susceptibility to mycobacterial infection. J Clin Invest 1998;101:2364-9.
77. Gangadharam PR, Perumal VK, Farhi DC, LaBrecque J. The beige mouse model for Mycobacterium avium complex (MAC) disease: optimal conditions for the host and parasite. Tubercle 1989;70:257-71.
78. Harshan KV, Gangadharam PR. In vivo depletion of natural killer cell activity leads to enhanced multiplication of Mycobacterium avium complex in mice. Infect Immun 1991;59:2818-21.
79. Bermudez LE, Young LS. Natural killer cell-dependent mycobacteriostatic and mycobactericidal activity in human macrophages. J Immunol 1991;146: 265-70.
80. Bermudez LE, Kolonoski P, Young LS. Natural killer cell activity and macrophage-dependent inhibition of growth or killing of Mycobacterium avium complex in a mouse model. J Leukoc Biol 1990;47: 135-41.
81. Bermudez LE, Wu M, Young LS. Interleukin-12-stimulated natural killer cells can activate human macrophages to inhibit growth of Mycobacterium avium. Infect Immun 1995;63:4099-104.
82. Wagner D, Sangari FJ, Kim S, Petrofsky M, Bermudez LE: Mycobacterium avium infection of macrophages results in progressive suppression of interleukin-12 production in vitro and in vivo. J Leukocyte Biol 2002;71-7.
83. Atkinson S, Valadas E, Smith SM, Lukey PT, Dockrell HM. Monocyte-derived macrophage cytokine responses induced by M. bovis BCG. Tuber Lung Dis 2000;80:197-207.
84. Castro AG, Silva RA, Appelberg R. Endogenously produced IL-12 is required for the induction of protective T cells during Mycobacterium avium infections in mice. J Immunol 1995;155:2013-9.
85. Doherty TM, Sher A. IL-12 promotes drug-induced clearance of Mycobacterium avium infection in mice. J Immunol 1998;160:5428-35.
86. Saunders BM, Zhan Y, Cheers C. Endogenous interleukin-12 is involved in resistance of mice to Mycobacterium avium complex infection. Infect Immun 1995;63:4011-5.
87. Kato T, Hakamada R, Yamane H, Nariuchi H. Induction of IL-12 p40 messenger RNA expression and IL-12 production of macrophages via CD40-CD40 ligand interaction. J Immunol 1996;156:3932-8.
88. Campbell KA, Ovendale PJ, Kennedy MK, Fanslow WC, Reed SG, Maliszewski CR. CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity 1996;4:283-9.
89. Samten B, Thomas EK, Gong J, Bames PF. Depressed CD40 ligand expression contributes to reduced gamma interferon production in human tuberculosis. Infect Immun 2000;68:3002-6.
90. Hayashi T, Rao SP, Meylan PR, Kombluth RS, Catanzaro A. Role of CD40 ligand in Mycobacterium avium infection. Infect Immun 1999;67:3558-65.
91. Bermudez LE. Production of transforming growth factor-beta by Mycobacterium avium-infected human macrophages is associated with unresponsiveness to IFN-gamma. J Immunol 1993;150:1838-45.
92. Champsi J, Young LS, Bermudez LE. Production of TNF-alpha, IL-6 and TGF-beta, and expression of receptors for TNF-alpha and IL-6, during murine Mycobacterium avium infection. Immunology 1995;84: 549-54.
93. Bermudez LE, Champsi J. Infection with Mycobacterium avium induces production of interleukin-10 (IL-10), and administration of anti-IL-10 antibody is associated with enhanced resistance to infection in mice. Infect Immun 1993;61:3093-7.
94. Denis M, Ghadirian E. IL-10 neutralization augments mouse resistance to systemic Mycobacterium avium infections. J Immunol 1993;151:5425-30.
95. Sannento A, Appelberg R. Involvement of reactive oxygen intermediates in tumor necrosis factor alpha-dependent bacteriostasis of Mycobacterium avium. Infect Immun 1996;64:3224-30.
96. Gomes MS, Florido M, Pais TF, Appelberg R. Improved clearance of Mycobacterium avium upon disruption of the inducible nitric oxide synthase gene. J Immunol 1999;162:6734-9.
97. Appelberg R, Orme IM. Effector mechanisms involved in cytokine-mediated bacteriostasis of Mycobacterium avium infections in murine macrophages. Immunology 1993;80:352-9.
98. Bermudez LE. Differential mechanisms of intracellular killing of Mycobacterium avium and Listeria monocytogenes by activated human and murine macrophages. The role of nitric oxide. Clin Exp Immunol 1993;91:277-81.
99. Wang T, Lafuse WP, Zwilling BS. Regulation of toll-like receptor 2 expression by macrophages following Mycobacterium avium infection. J Immunol 2000; 165:6308-13.
100. Means TK, Jones BW, Schromm AB, Shurtleff BA, Smith JA, Keane J, et al. Differential effects of a Toll-like receptor antagonist on Mycobacterium tuberculosis-induced macrophage responses. J Immunol 2001; 166:4074-82.
101. Bermudez LE, Young LS. Tumor necrosis factor, alone or in combination with IL-2, but not IFN- gamma, is associated with macrophage killing of Mycobacterium avium complex. J Immunol 1988;140: 3006-13.
102. Appelberg R, Castro AG, Pedrosa J, Silva RA, Orme IM, Minoprio P. Role of gamma interferon and tumor necrosis factor alpha during T-cell- independent and -dependent phases of Mycobacterium avium infection. Infect Immun 1994;62:3962-71.
103. Bermudez LE, Young LS. Recombinant granulocyte-macrophage colony-stimulating factor activates human macrophages to inhibit growth or kill Mycobacterium avium complex. J Leukoc Biol 1990;48: 67-73.
104. Bermudez LE, Martinelli J, Petrofsky M, Kolonoski P, Young LS. Recombinant granulocyte-macrophage colony-stimulating factor enhances the effects of antibiotics against Mycobacterium avium complex infection in the beige mouse model. J Infect Dis 1994; 169:575-80.
105. Sugawara I, Yamada H, Kaneko H, Mizuno S, Takeda K, Akira S. Role of interleukin-18 (IL-18) in mycobacterial infection in IL-18-gene-disrupted mice. Infect Immun 1999;67:2585-9.
106. Bermudez LE, Petrofsky M. Host defense against Mycobacterium avium does not have an absolute requirement for major histocompatibility complex class I-restricted T cells. Infect Immun 1999;67:3108-11.
107. Gilbertson B, Zhong J, Cheers C. Anergy, IFN-gamma production, and apoptosis in terminal infection of mice with Mycobacterium avium. J Immunol 1999; 163:2073-80.
108. Roger PM, Bermudez LE. Infection of mice with Mycobacterium avium primes CD8+ lymphocytes for apoptosis upon exposure to macrophages. Clin Immunol 2001;99:378-86.
109. Saunders BM, Frank AA, Cooper AM, Orme IM. Role of gamma delta T cells in immunopathology of pulmonary Mycobacterium avium infection in mice. Infect Immun 1998;66:5508-14.
110. Witzig RS, Fazal BA, Mera RM, Mushatt DM, Dejace PM, Greer DL, et al. Clinical manifestations and implications of coinfection with Mycobacterium kansasii and human immunodeficiency virus type 1. Clin Infect Dis 1995;21:77-85.
111. Kaustova J, Chmelik M, Ettlova D, Hudec V, Lazarova H, Richtrova S. Disease due to Mycobacterium kansasii in the Czech Republic: 1984-89. Tuber Lung Dis 1995;76:205-9.
112. Bailey RK, Wyles S, Dingley M, Hesse F, Kent GW. The isolation of high catalase Mycobacterium kansasii from tap water. Am Rev Respir Dis 1970;101: 430-1.
113. Maniar AC, Vanbuckenhout LR. Mycobacterium kansasii from an environmental source. Can J Public Health 1976;67:59-60.
114. McSwiggan DA, Collins CH. The isolation of M. kansasii and M. xenopi from water systems. Tubercle 1974;55:291-7.
115. Powell Jr. BL, Steadham JE. Improved technique for isolation of Mycobacterium kansasii from water. J Clin Microbiol 1981;13:969-75.
116. Steadham JE. High-catalase strains of Mycobacterium kansasii isolated from water in Texas. J Clin Microbiol 1980;11:496-8.
117. Wright EP, Collins CH, Yates MD. Mycobacterium xenopi and Mycobacterium kansasii in a hospital water supply. J Hosp Infect 1985;6:175-8.
118. Joynson DH. Water: the natural habitat of Mycobacterium kansasii? Tubercle 1979;60:77-81.
119. Chapman JS, Bernard JS, Speight M. Isolation of mycobacteria from raw milk. J Respir Dis 1965;14: 212-7.
120. Comer LA, Barrett RH, Lepper AW, Lewis V, Pearson CW. A survey of mycobacteriosis of feral figs in the Northern Territory. Aust Vet J 1981;57:537-42.
121. Wolinsky E, Rynearson TK. Mycobacteria in soil and their relation to disease-associated strain. Am Rev Respir Dis 1968;97:1032-7,
122. Ahn CH, Lowell JR, Onstad GD, Shuford EH, Hurst GA. A demographic study of disease due to Mycobacterium kansasii or M. intracellulare-avium in Texas. Chest 1979;75:120-5.
123. Ross BC, Jackson K, Yang M, Sievers A, Dwyer B. Identification of a genetically disttince subspeices of Mycobacterium kansasii. J Clin Microbiol 1992;30: 2930-3.
124. Szulga T, Jenkins PA, Marks J. Thin-layer chromatography of mycobacterial lipids as an aid to classification; Mycobacterium kansasii; and Mycobacterium marinum (balnei). Tubercle 1966;47:130-6.
125. Yang M, Ross BC, Dwyer B. Isolation of a DNA probe for identification of Mycobacterium kansasii, including the genetic subgroup. J Clin Microbiol 1993;31:2769-72.
126. Picardeau M, Prod'Hom G, Raskine L, LePennec MP, Vincent V. Genotypic characterization of five subspecies of Mycobacterium kansasii. J Clin Microbiol 1997;35:25-32.
127. Tortoli E, Simonetti MT, Lacchini C, Penati V, Piersimoni C, Morbiducci V. Evaluation of a commercial DNA probe assay for the identification of Mycobacterium kansasii. Eur J Clin Microbiol Infect Dis 1994;13:264-7.
128. Alcaide F, Richter I, Bemasconi C, Springer B, Hagenau C, Schulze-Robbecke R, et al. Heterogeneity and clonality among isolates of Mycobacterium kansasii: implications for epidemiological and pathogenicity studies. J Clin Microbiol 1997;35:1959-64.
129. Lebrun L, Espinasse F, Poveda JD, Vincent-Levy-Frebault V. Evaluation of nonradioactive DNA probes for identification of mycobacteria. J Clin Microbiol 1992;30:2476-8.
130. Le Cabec V, Cols C, Maridonneau-Parini I. Nonopsonic phagocytosis of zymosan and Mycobacterium kansasii by CR3 (CD11b/CD18) involves distinct molecular determinants and is or is not coupled with NADPH oxidase activation. Infect Immun 2000;68: 4736-45.
131. Viallier J, Viallier G. An inventory of naturally-occurring mycobacteria. Ann Soc Belg Med Trop 1973;53: 361-71.
132. Paull A. An environmental study of the opportunist mycobacteria. Med Lab Technol 1973;30:11-9.
133. Schulze-Robbecke R, Janning B, Fischeder R. Occurrence of mycobacteria in biofilm samples. Tuber Lung Dis 1992;73:141-4.
134. Carson LA, Petersen NJ, Favero MS, Aguero SM. Growth characteristics of atypical mycobacteria in water and their comparative resistance to disinfectants. Appl Environ Microbiol 1978;36:839-46.
135. Fischeder R, Schulze-Robbecke R, Weber A. Occurrence of mycobacteria in drinking water samples. Zentralbl Hyg Umweltmed 1991;192:154-8.
136. Collins FM. Bactericidal activity of alkaline glutaraldehyde solution against a number of atypical mycobacterial species. J Appl Bacteriol 1986;61:247-51.
137. Steingrube VA, Wallace Jr. RJ, Steele LC, Pang YJ. Mercuric reductase activity and evidence of broad-spectrum mercury resistance among clinical isolates of rapidly growing mycobacteria. Antimicrob Agents Chemother 1991;35:819-23.
138. Lowry PW, Jarvis WR, Oberle AD, Bland LA, Silberman R, Bocchini Jr. JA, et al. Mycobacterium chelonae causing otitis media in an ear-nose-and-throat practice. N Engl J Med 1988;319:978-82.
139. Wenger JD, Spika JS, Smithwick RW, Pryor V, Dodson DW, Carden GA, et al. Outbreak of Mycobacterium chelonae infection associated with use of jet injectors. JAMA 1990;264:373-6.
140. Brown TH. The rapidly growing mycobacteria-Mycobacterium fortuitum and Mycobacterium chelonei. Infect Control 1985;6:283-8.
141. Wallace Jr RJ, Swenson JM, Silcox VA, Good RC, Tschen JA, Stone MS. Spectrum of disease due to rapidly growing mycobacteria. Rev Infect Dis 1983; 5:657-79.
142. Ingram CW, Tanner DC, Durack DT, Kemodle Jr GW, Corey GR. Disseminated infection with rapidly growing mycobacteria. Clin Infect Dis 1993;16:463-71.
143. Wallace Jr RJ, Brown BA, Griffith DE. Nosocomial outbreaks/pseudo-outbreaks caused by nontuberculous mycobacteria. Annu Rev Microbiol 1998;52: 453-90.